Last reviewed · How we verify

Bacille Calmette-Guérin (BCG) — Competitive Intelligence Brief

Bacille Calmette-Guérin (BCG) (Bacille Calmette-Guérin (BCG)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine / Immunotherapy. Area: Oncology / Immunology.

marketed Live attenuated vaccine / Immunotherapy Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation Oncology / Immunology Biologic Live · refreshed every 30 min

Target snapshot

Bacille Calmette-Guérin (BCG) (Bacille Calmette-Guérin (BCG)) — TASK Applied Science. BCG is a live attenuated mycobacterial vaccine that stimulates innate and adaptive immune responses to enhance anti-tumor immunity and treat bladder cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bacille Calmette-Guérin (BCG) TARGET Bacille Calmette-Guérin (BCG) TASK Applied Science marketed Live attenuated vaccine / Immunotherapy Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation
BCG Solution BCG Solution Alliance for Clinical Trials in Oncology marketed Live attenuated vaccine / Immunotherapy
Bacillus Calmette-Guerin (BCG) Bacillus Calmette-Guerin (BCG) Massachusetts General Hospital marketed Live attenuated vaccine / Immunotherapy
Bacillus Calmette-Guerin Vaccine Intravesical Bacillus Calmette-Guerin Vaccine Intravesical Nottingham University Hospitals NHS Trust phase 3 Live attenuated vaccine / Immunotherapy
Bacillus Calmette-Guérin (BCG) Bacillus Calmette-Guérin (BCG) Memorial Sloan Kettering Cancer Center phase 3 Live attenuated vaccine / Immunotherapy Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation
BCG for Injection BCG for Injection Suzhou Suncadia Biopharmaceuticals Co., Ltd. phase 3 Live attenuated vaccine / Immunotherapy Toll-like receptors (TLR2, TLR4); non-specific immune activation
Bacillus Calmette-Guérin Bacillus Calmette-Guérin Massachusetts General Hospital phase 3 Live attenuated vaccine / Immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine / Immunotherapy class)

  1. Massachusetts General Hospital · 2 drugs in this class
  2. Memorial Sloan Kettering Cancer Center · 1 drug in this class
  3. Alliance for Clinical Trials in Oncology · 1 drug in this class
  4. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class
  5. TASK Applied Science · 1 drug in this class
  6. Verity Pharmaceuticals Inc. · 1 drug in this class
  7. Nottingham University Hospitals NHS Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bacille Calmette-Guérin (BCG) — Competitive Intelligence Brief. https://druglandscape.com/ci/bacille-calmette-gu-rin-bcg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: